Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic
On Tuesday, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced that it will present Phase 1 results in healthy volunteers and new Phase 1b interim data in cystic fibrosis (CF) for ARCT-032 at the European Cystic Fibrosis Conference.
週二，Arcturus Therapeutics Holdings Inc.（納斯達克股票代碼：ARCT）宣佈，將在歐洲囊性纖維化會議上公佈健康志願者的第一階段結果和 ARCT-032 的囊性纖維化（CF）1b期新中期數據。
"We were pleased to observe ARCT-032 treatments for the first four patients were generally safe and well tolerated with no serious adverse events," said Joseph Payne, President & CEO of Arcturus Therapeutics. "Furthermore, we observed an encouraging trend towards lung function improvements in the first four CF participants after only two inhaled administrations."
Arcturus Therapeutics總裁兼首席執行官約瑟夫·佩恩表示：“我們很高興看到前四名患者的 ARCT-032 治療總體上是安全的，耐受性良好，沒有嚴重的不良事件。”“此外，我們觀察到前四名CF參與者在僅兩次吸入給藥後肺功能改善的趨勢令人鼓舞。”
"The absolute change in percent predicted FEV1 (Forced Expiratory Volume in 1 second) in the first four CF participants was observed to be an average of 4.0% at day 8," said Dr. Juergen Froehlich, Chief Medical Officer of Arcturus Therapeutics.
Arcturus Therapeutics首席醫學官尤爾根·弗羅利****說：“據觀察，前四名CF參與者的FEV1（1秒內強制呼氣量）的絕對變化百分比在第8天平均爲4.0％。”
William Blair notes that the results are encouraging, although several key questions remain ahead of the presentation.
威廉·布萊爾指出，儘管演講前還有幾個關鍵問題，但結果令人鼓舞。
William Blair's analyst notes it is crucial to determine if the patients were using Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Trikafta or if they had a genetic deletion, making them ineligible for CFTR modulator therapy.
威廉·布萊爾的分析師指出，至關重要的是要確定患者是否在使用Vertex Pharmicals Incorporated（納斯達克股票代碼：VRTX）的Trikafta，或者他們是否存在基因缺失，這使他們沒有資格接受CFTR調節劑治療。
A 4% improvement over Trikafta would be significant, especially since Vertex's second-generation Vanza triple did not outperform the current Trikafta treatment. Thus, an additional 4% improvement could be impactful.
與Trikafta相比，改善4％將是顯著的，尤其是因爲Vertex的第二代Vanza三合一的表現並未超過目前的Trikafta療法。因此，再提高4％可能會產生影響。
As William Blair looks forward to additional detail at the conference presentation on June 7 and the planned company update on July 1, the preliminary results are encouraging if able to show an improvement on top of the standard of care or in those patients who are ineligible for current CFTR modulators.
威廉·布萊爾期待在6月7日的會議演講和計劃於7月1日發佈的公司最新情況中獲得更多細節，如果能夠顯示護理標準有所改善，或者沒有資格使用當前CFTR調節劑的患者，初步結果令人鼓舞。
Arcturus' current share value is primarily driven by Kostaive commercial expectations, CSL profit sharing from respiratory vaccine programs, and the company's cash position, with minimal value attributed to the therapeutic pipeline.
Arcturus當前的股票價值主要由Kostaive的商業預期、CSL的呼吸疫苗項目利潤分成以及公司的現金狀況所驅動，而歸因於治療渠道的價值微乎其微。
The analyst reaffirms the Outperform rating.
分析師重申了跑贏大盤的評級。
Price Action: ARCT shares are up 21.90% at $37.07 at the last check on Tuesday.
價格走勢：在週二的最後一次檢查中，ARCT股價上漲21.90％，至37.07美元。
譯文內容由第三人軟體翻譯。